Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
Alvarez-Cermeño
José C
JC
Masjuan
Jaime
J
Villar
Luisa M
LM
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001921:Brain / Q000473:pathology; D003937:Diagnosis, Differential; D006801:Humans; D016899:Interferon-beta / Q000009:adverse effects*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000473:pathology*; D000069442:Natalizumab
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D016899:Interferon-beta